{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:27Z","timestamp":1784005707679,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate 18 months' results of a strict anti\u2013vascular endothelial growth factor protocol for radiation maculopathy following proton therapy in choroidal melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective, comparative, nonrandomized study of 74 radiation maculopathy patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia, or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal anti\u2013vascular endothelial growth factors (bevacizumab\/ranibizumab: 46\/6) every two months for the first and every 3 months for the second year, with minimum 12 months' follow-up. The control group consisted of 22 patients having declined this treatment. Best-corrected visual acuity, spectral domain-optical coherence tomography and optical coherence tomography angiography were recorded at baseline, 6, 12, and 18 months. The foveal avascular zone and capillary density were measured at the superficial capillary plexus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Radiation maculopathy was diagnosed at 2 years (1.5\u20133.5) after proton therapy. Best-corrected visual acuity at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 logarithm of the minimum angle of resolution, but decreased in the control group from 0.5, 0.9 to 1.0 logarithm of the minimum angle of resolution respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001 at 12 months). Simultaneously, foveal avascular zone enlargement was less in the study (from 0.377, 0.665 to 0.744 mm<jats:sup>2<\/jats:sup>) than control group (from 0.436, 1.463 to 2.638 mm<jats:sup>2<\/jats:sup>) (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05 at 12 months). CMT (280 and 276 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m) and capillary density (37% and 38%, at baseline, respectively) did not evolve significantly different.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Intravitreal anti\u2013vascular endothelial growth factors, every 2 months for the first and every 3 months for the second year, slow down, over up to 18 months, vision loss and anatomical degradation in radiation maculopathy following proton therapy for choroidal melanoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003105","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:59:50Z","timestamp":1610546390000},"page":"1883-1891","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["EIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY"],"prefix":"10.1097","volume":"41","author":[{"given":"Chiara M.","family":"Eandi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland; and"},{"name":"Department of Surgical Science, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Polito","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Schalenbourg","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Zografos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajo.2017.06.008","article-title":"Optical coherence tomography angiography of macular features after proton beam radiotherapy for small choroidal melanoma","volume":"181","author":"Sellam","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/IAE.0000000000002615","article-title":"Identification and classification of macular biomarkers related to visual acuity in radiation maculopathy: a multimodal imaging study","volume":"40","author":"Parrozzani","year":"2020","journal-title":"Retina"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1167\/iovs.17-22324","article-title":"Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity","volume":"58","author":"Matet","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20250609","first-page":"T2","article-title":"Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma","volume":"114","author":"Kim","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/ICU.0000000000000141","article-title":"Current treatments and preventive strategies for radiation retinopathy","volume":"26","author":"Reichstein","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/IAE.0000000000002200","article-title":"Intravitreal anti-vascular endothelial growth factor treatment at 2-month intervals reduces foveal avascular zone enlargement and vision loss in radiation maculopathy: a Pilot Study","volume":"39","author":"Daruich","year":"2019","journal-title":"Retina"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00417-019-04347-6","article-title":"Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma","volume":"257","author":"Fallico","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.oret.2019.02.009","article-title":"Aflibercept for radiation maculopathy study: a prospective, randomized clinical study","volume":"3","author":"Murray","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5301\/ejo.5000670","article-title":"Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study","volume":"26","author":"Finger","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R11-20250609","first-page":"1739","article-title":"Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity","volume":"6","author":"Shah","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","article-title":"Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma","volume":"121","author":"Shah","year":"2014","journal-title":"Ophthalmology"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","article-title":"Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma. Comparison with nonrandomized historical control individuals","volume":"138","author":"Shields","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1097\/IAE.0000000000000844","article-title":"Noninvasive grading of radiation retinopathy: the use of optical coherence tomography angiography","volume":"35","author":"Veverka","year":"2015","journal-title":"Retina"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/IAE.0000000000001021","article-title":"Optical coherence tomography angiography of the macula after plaque radiotherapy of choroidal melanoma: comparison of irradiated versus non-irradiated eyes in 65 patients","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajo.2014.07.002","article-title":"Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma","volume":"158","author":"Mantel","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ophtha.2019.06.016","article-title":"OCT Angiography metrics predict progression of diabetic retinopathy and development of diabetic macular edema: a prospective study","volume":"126","author":"Sun","year":"2019","journal-title":"Ophthalmology"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ICU.0b013e3283386687","article-title":"Classification and treatment of radiation maculopathy","volume":"21","author":"Horgan","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00055735-199406000-00011","article-title":"Ionizing radiation and the retina","volume":"5","author":"Archer","year":"1994","journal-title":"Curr Opin Ophthalmol"},{"key":"R20-20250609","first-page":"321","article-title":"Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle","volume":"7","author":"Rusovici","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-03-0426","article-title":"Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor","volume":"10","author":"Nordal","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R22-20250609","first-page":"3348","article-title":"Hypoxia in radiation-induced blood-spinal cord barrier breakdown","volume":"61","author":"Li","year":"2001","journal-title":"Cancer Res"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41598-018-38248-1","article-title":"Retinal microvasculature and visual acuity after intravitreal aflibercept in diabetic macular edema: an optical coherence tomography angiography study","volume":"9","author":"Busch","year":"2019","journal-title":"Sci Rep"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0002-9440(10)65044-4","article-title":"Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)","volume":"156","author":"Miyamoto","year":"2000","journal-title":"Am J Pathol"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)64869-9","article-title":"Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo","volume":"160","author":"Joussen","year":"2002","journal-title":"Am J Pathol"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm877","article-title":"Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease","volume":"9","author":"Ishida","year":"2003","journal-title":"Nat Med"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T16:01:25Z","timestamp":1749484885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003105","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}